1. Home
  2. MLYS vs HLIT Comparison

MLYS vs HLIT Comparison

Compare MLYS & HLIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • HLIT
  • Stock Information
  • Founded
  • MLYS 2019
  • HLIT 1988
  • Country
  • MLYS United States
  • HLIT United States
  • Employees
  • MLYS N/A
  • HLIT N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • HLIT Radio And Television Broadcasting And Communications Equipment
  • Sector
  • MLYS Health Care
  • HLIT Technology
  • Exchange
  • MLYS Nasdaq
  • HLIT Nasdaq
  • Market Cap
  • MLYS 1.0B
  • HLIT 1.0B
  • IPO Year
  • MLYS 2023
  • HLIT 1995
  • Fundamental
  • Price
  • MLYS $13.48
  • HLIT $8.88
  • Analyst Decision
  • MLYS Strong Buy
  • HLIT Buy
  • Analyst Count
  • MLYS 4
  • HLIT 6
  • Target Price
  • MLYS $27.00
  • HLIT $12.33
  • AVG Volume (30 Days)
  • MLYS 667.1K
  • HLIT 661.8K
  • Earning Date
  • MLYS 08-12-2025
  • HLIT 07-28-2025
  • Dividend Yield
  • MLYS N/A
  • HLIT N/A
  • EPS Growth
  • MLYS N/A
  • HLIT N/A
  • EPS
  • MLYS N/A
  • HLIT 0.44
  • Revenue
  • MLYS N/A
  • HLIT $689,797,000.00
  • Revenue This Year
  • MLYS N/A
  • HLIT N/A
  • Revenue Next Year
  • MLYS N/A
  • HLIT $21.63
  • P/E Ratio
  • MLYS N/A
  • HLIT $20.01
  • Revenue Growth
  • MLYS N/A
  • HLIT 20.53
  • 52 Week Low
  • MLYS $8.24
  • HLIT $7.91
  • 52 Week High
  • MLYS $18.38
  • HLIT $15.46
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 35.32
  • HLIT 43.09
  • Support Level
  • MLYS $12.98
  • HLIT $8.67
  • Resistance Level
  • MLYS $16.67
  • HLIT $9.74
  • Average True Range (ATR)
  • MLYS 0.81
  • HLIT 0.24
  • MACD
  • MLYS -0.33
  • HLIT -0.06
  • Stochastic Oscillator
  • MLYS 13.56
  • HLIT 19.63

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About HLIT Harmonic Inc.

Harmonic Inc engaged in broadband access solutions that enable broadband operators to more efficiently and effectively deploy high-speed internet for data, voice, and video services for their customers and versatile and high-performance video delivery software, products, system solutions and services that enable its customers to efficiently create, prepare, store, playout and deliver a full range of high-quality broadcast and streaming video services to consumer devices, including televisions, personal computers, laptops, tablets, and smartphones. It has two segments, Broadband which provides broadband access solutions and related services, and Others; and Video business provides video processing and production and playout solutions and services, and Others.

Share on Social Networks: